Pfizer unveils $214M biotech plant

Pfizer has opened a new, $214 million biotech manufacturing facility in Sweden. The 68,000-square-foot plant will make recombinant proteins based on e. coli and yeast as well as a branded human growth hormone. But Pfizer says that it built the plant to accommodate the production of a variety of therapies. Report

Suggested Articles

Novartis, Otsuka, Pfizer and Sanofi will use technology from Verily’s Project Baseline to carry out clinical studies in various disease areas.

Ocular Therapeutix’s drug-eluting tear duct plug for glaucoma fell just short of the primary endpoint of its first phase 3 trial.

The East Coast investor will primarily provide debt financing to enable companies to reach milestones with minimal equity dilution.